<DOC>
	<DOCNO>NCT02093910</DOCNO>
	<brief_summary>Bortezomib important drug treatment multiple myeloma ( MM ) , peripheral neuropathy ( PN ) significant dose-limiting toxicity bortezomib typically occur within first course bortezomib , reach plateau cycle 5 . Up , effective prophylaxis develop PN . Monosialotetrahexosylganglioside , nerve-protecting drug , often used promote growth nerve , function restoration damage nerve.Thus , investigator hypothesize combination Monosialotetrahexosylganglioside bortezomib reduce incidence rate peripheral neuropathy ( PN ) promote relief peripheral neuropathy ( PN ) multiple myeloma ( MM ) patient .</brief_summary>
	<brief_title>Efficacy Monosialotetrahexosylganglioside Prophylactic Treatment Bortezomib-induced Peripheral Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Histologic diagnosis multiple myeloma ; Age:1880 year ; Eastern Cooperative Oncology Group ( ECOG ) status 03 , Estimated survival time &gt; 3 month ; Acceptable liver function ( bilirubin＜2.5×ULN , Alanine transaminase ( ALT ) Aspartate Aminotransferase ( AST ) ＜2.5×ULN ) , No history malignancy ; No previous treatment include chemotherapy , radiotherapy , target therapy stem cell transplantation ; No serious disease conflict treatment present trial ; No concurrent treatment conflict treatment present trial ; Voluntary participation sign informed consent . The patient condition : clinically significant ventricular tachycardia ( VT ) , atrial fibrillation ( AF ) , heart block , myocardial infarction ( MI ) , congestive heart failure ( CHF ) , symptomatic coronary artery heart disease require medication ; The patient participate clinical trial within 30 day enrollment participate clinical study ; The patient neuropathy ; The patient mentally ill / unable obtain informed consent ; The patient drug addiction , alcohol abuse affect longterm evaluation test result ; The patient pregnancy , lactation woman childbearing age want take contraceptive measure subject ; The patient history allergy test drug ; The patient suitable participate investigator judge researcher .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>peripheral neuropathy</keyword>
	<keyword>prophylaxis</keyword>
</DOC>